VAXCYTE, INC. Operating Income
VAXCYTE, INC. (PCVX) reported Operating Income of -$302.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- VAXCYTE, INC. operating income (loss) for the quarter ending 2026-06-30 was -$302.78M.
- VAXCYTE, INC. operating income (loss) for the quarter ending 2026-03-31 was -$345.85M.
- VAXCYTE, INC. operating income (loss) for the quarter ending 2025-12-31 was -$274.28M.
- VAXCYTE, INC. operating income (loss) for the quarter ending 2025-09-30 was -$242.38M.
- VAXCYTE, INC. operating income (loss) for fiscal 2025 was -$923.67M.
- VAXCYTE, INC. operating income (loss) for fiscal 2024 was -$569.55M.
- VAXCYTE, INC. operating income (loss) for fiscal 2023 was -$468.04M.
- VAXCYTE, INC. operating income (loss) for fiscal 2022 was -$232.26M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$302.78M 10-Q · filed 2026-08-05 | -$648.63M 10-Q · filed 2026-08-05 | -$922.91M derived: sum of 3 quarters · filed 2026-08-05 | -$1.17B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$345.85M 10-Q · filed 2026-05-06 | -$620.13M derived: sum of 2 quarters · filed 2026-05-06 | -$862.51M derived: sum of 3 quarters · filed 2026-05-06 | -$1.09B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$274.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$516.66M derived: sum of 2 quarters · filed 2026-02-24 | -$742.88M derived: sum of 3 quarters · filed 2026-08-05 | -$923.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$242.38M 10-Q · filed 2025-11-04 | -$468.60M derived: sum of 2 quarters · filed 2026-08-05 | -$649.39M 10-Q · filed 2025-11-04 | -$811.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$226.22M 10-Q · filed 2026-08-05 | -$407.01M 10-Q · filed 2026-08-05 | -$569.18M derived: sum of 3 quarters · filed 2026-08-05 | -$709.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$180.79M 10-Q · filed 2026-05-06 | -$342.96M derived: sum of 2 quarters · filed 2026-05-06 | -$482.89M derived: sum of 3 quarters · filed 2026-05-06 | -$635.87M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$162.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$302.09M derived: sum of 2 quarters · filed 2026-02-24 | -$455.07M derived: sum of 3 quarters · filed 2026-02-24 | -$569.55M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$139.92M 10-Q · filed 2025-11-04 | -$292.90M derived: sum of 2 quarters · filed 2025-11-04 | -$407.38M 10-Q · filed 2025-11-04 | -$604.05M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$152.98M 10-Q · filed 2025-08-06 | -$267.45M 10-Q · filed 2025-08-06 | -$464.13M derived: sum of 3 quarters · filed 2026-02-24 | -$577.15M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$114.47M 10-Q · filed 2025-05-07 | -$311.15M derived: sum of 2 quarters · filed 2026-02-24 | -$424.17M derived: sum of 3 quarters · filed 2026-02-24 | -$511.32M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$196.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$309.70M derived: sum of 2 quarters · filed 2026-02-24 | -$396.85M derived: sum of 3 quarters · filed 2026-02-24 | -$468.04M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$113.03M 10-Q · filed 2024-11-05 | -$200.17M derived: sum of 2 quarters · filed 2024-11-05 | -$271.37M 10-Q · filed 2024-11-05 | -$357.94M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$87.15M 10-Q · filed 2024-08-06 | -$158.34M 10-Q · filed 2024-08-06 | -$244.91M derived: sum of 3 quarters · filed 2025-02-25 | -$303.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$71.19M 10-Q · filed 2024-05-08 | -$157.76M derived: sum of 2 quarters · filed 2025-02-25 | -$216.34M derived: sum of 3 quarters · filed 2025-02-25 | -$264.23M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$86.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$145.15M derived: sum of 2 quarters · filed 2025-02-25 | -$193.04M derived: sum of 3 quarters · filed 2025-02-25 | -$232.26M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$58.58M 10-Q · filed 2023-11-06 | -$106.46M derived: sum of 2 quarters · filed 2023-11-06 | -$145.68M 10-Q · filed 2023-11-06 | -$175.53M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$47.89M 10-Q · filed 2023-08-08 | -$87.11M 10-Q · filed 2023-08-08 | -$116.95M derived: sum of 3 quarters · filed 2024-02-27 | -$143.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$39.22M 10-Q · filed 2023-05-08 | -$69.07M derived: sum of 2 quarters · filed 2024-02-27 | -$96.02M derived: sum of 3 quarters · filed 2024-02-27 | -$119.75M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$29.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$56.80M derived: sum of 2 quarters · filed 2024-02-27 | -$80.53M derived: sum of 3 quarters · filed 2024-02-27 | -$103.67M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$26.95M 10-Q · filed 2022-11-07 | -$50.68M derived: sum of 2 quarters · filed 2022-11-07 | -$73.82M 10-Q · filed 2022-11-07 | -$93.28M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$23.73M 10-Q · filed 2022-08-08 | -$46.87M 10-Q · filed 2022-08-08 | -$66.33M derived: sum of 3 quarters · filed 2022-08-08 | -$87.63M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$23.14M 10-Q · filed 2022-05-09 | -$42.60M derived: sum of 2 quarters · filed 2022-05-09 | -$63.90M derived: sum of 3 quarters · filed 2022-05-09 | -$85.13M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$19.45M 10-K · filed 2021-03-29 | -$40.76M derived: sum of 2 quarters · filed 2021-11-10 | -$61.98M derived: sum of 3 quarters · filed 2021-11-10 | -$89.58M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$21.31M 10-Q · filed 2021-11-10 | -$42.53M derived: sum of 2 quarters · filed 2021-11-10 | -$70.13M 10-Q · filed 2021-11-10 | -$85.97M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$21.22M 10-Q · filed 2021-08-11 | -$48.82M 10-Q · filed 2021-08-11 | -$64.66M derived: sum of 3 quarters · filed 2021-08-11 | -$76.80M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$27.60M 10-Q · filed 2021-05-11 | -$43.43M derived: sum of 2 quarters · filed 2021-05-11 | -$55.57M derived: sum of 3 quarters · filed 2021-05-11 | -$67.81M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$15.84M 10-K · filed 2021-03-29 | -$27.98M derived: sum of 2 quarters · filed 2021-03-29 | -$40.21M derived: sum of 3 quarters · filed 2021-03-29 | -$54.15M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$12.14M 10-K · filed 2021-03-29 | -$24.37M derived: sum of 2 quarters · filed 2021-03-29 | -$38.31M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$12.23M 10-K · filed 2021-03-29 | -$26.18M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$13.94M 10-K · filed 2021-03-29 | |||
| 2018-12-31 | -$35.53M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |